ClinVar Miner

Submissions for variant NM_000059.4(BRCA2):c.7961T>C (p.Leu2654Pro)

gnomAD frequency: 0.00001  dbSNP: rs80359023
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000575154 SCV000666056 likely pathogenic Hereditary cancer-predisposing syndrome 2024-05-14 criteria provided, single submitter clinical testing The p.L2654P variant (also known as c.7961T>C), located in coding exon 16 of the BRCA2 gene, results from a T to C substitution at nucleotide position 7961. The leucine at codon 2654 is replaced by proline, an amino acid with similar properties. This variant is located in the DNA binding domain of BRCA2. This alteration was non-functional in a cell-based homology-directed DNA break repair (HDR) functional assay (Ambry internal data; Guidugli L et al. Cancer Res. 2013 Jan;73(1):265-75; Hart SN et al. Genet Med, 2019 01;21:71-80). This alteration is also predicted to destabilize the local structure and disrupt the protein binding ability of BRCA2 (Yang H et al. Science 2002 Sep;297:1837-48; Marston NJ et al. Mol. Cell. Biol. 1999 Jul;19:4633-42; Ambry internal data). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic.
Labcorp Genetics (formerly Invitae), Labcorp RCV001322453 SCV001513326 uncertain significance Hereditary breast ovarian cancer syndrome 2024-08-14 criteria provided, single submitter clinical testing This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 2654 of the BRCA2 protein (p.Leu2654Pro). This variant is present in population databases (rs80359023, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with BRCA2-related conditions. ClinVar contains an entry for this variant (Variation ID: 52448). An algorithm developed specifically for the BRCA2 gene suggests that this missense change is likely to be deleterious (PMID: 19043619). Experimental studies have shown that this missense change affects BRCA2 function (PMID: 23108138, 29394989, 29884841, 35736817). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
GeneDx RCV001550363 SCV001770677 uncertain significance not provided 2020-03-02 criteria provided, single submitter clinical testing Not observed at a significant frequency in large population cohorts (Lek 2016); In silico analysis supports that this missense variant does not alter protein structure/function; Published functional studies demonstrate a damaging effect: defective homology-directed repair activity (Guidugli 2013, Guidugli 2018); Also known as 8189T>C; This variant is associated with the following publications: (PMID: 29394989, 30374176, 29884841, 24323938, 23108138, 19043619)
All of Us Research Program, National Institutes of Health RCV000113845 SCV004845577 uncertain significance Breast-ovarian cancer, familial, susceptibility to, 2 2023-10-02 criteria provided, single submitter clinical testing This missense variant replaces leucine with proline at codon 2654 of the BRCA2 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have shown that this variant results in reduced or loss of homology-directed DNA repair activity (PMID: 23108138, 29394989). To our knowledge, this variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has been identified in 1/31406 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Breakthrough Genomics, Breakthrough Genomics RCV001550363 SCV005192116 uncertain significance not provided criteria provided, single submitter not provided
Breast Cancer Information Core (BIC) (BRCA2) RCV000113845 SCV000147228 uncertain significance Breast-ovarian cancer, familial, susceptibility to, 2 2003-10-29 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.